|
Samaritan
Hires Expert Marketing Specialist to Build Up Southeast
Europe Sales
Tuesday January 22, 2008 10:15
am ET
Return
to Homepage | See All News
Past
Marketing Manager for Biogen and Serono Pharma International
Brings Over Ten Years of Marketing Expertise for Europe
and Southeastern Europe
Samaritan
Pharmaceuticals, Inc. (OTC BB:SPHC.OB) a biopharmaceutical
company focused on developing innovative therapeutics
in the areas of CNS, cancer, cardiovascular, and infectious
diseases, has hired Themis Moustakas as its Southeast
European Specialty Prescription Pharmaceutical Marketing
Director.
Mr. Moustakas
has dedicated his career to pharmaceutical marketing
and has held positions at leading pharma companies,
including Serono Pharma International and Biogen. Since
2004, Mr. Moustakas has held marketing positions of
increasing responsibility at Serono Pharma International
in Zug, Switzerland. At Serono, he began as a Marketing/Sales
Manager of the Reproductive Health, Neurology, and Dermatology
division for emerging markets, then held the position
of the Country Manager of Southeastern Europe, and has
since served as the Regional Marketing Manager of Endocrinology
for CE Europe, Switzerland, Austria, Baltics, and Israel.
In subsequent years, Mr. Moustakas held management positions
marketing neurological products for multiple sclerosis
in France and Greece. Mr. Moustakas has a Bachelor of
Science in Pharmacy from the Aristotle University of
Thessaloniki, Greece and a Master of Arts in Marketing
from the University of Sunderland, U.K.
|
| "We
have in-licensed eleven specialty prescription
drugs to sell in Greece and Southeastern Europe
and are looking forward to increasing our drug
sales portfolio through additional in-licensing.
Themis was recruited by Dr. Christos Dakas, Managing
Director Europe and will join the incredible sales
team Dr. Dakas has built.''
Dr.
Janet Greeson
CEO Samaritan Pharmaceuticals |
|
"Themis
brings not only considerable experience with specialty sales
in Southeastern Europe, but also brings enormous enthusiasm
to grow our pharmaceutical sales there,'' commented Dr. Janet
Greeson, Samaritan Chief Executive Officer. "We have
in-licensed eleven specialty prescription drugs to sell in
Greece and Southeastern Europe and are looking forward to
increasing our drug sales portfolio through additional in-licensing.
Themis was recruited by Dr. Christos Dakas, Managing Director
Europe and will join the incredible sales team Dr. Dakas has
built.''
About
Samaritan Pharmaceuticals: "Transforming Today's
Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals
is a biopharmaceutical company focused on commercializing
new innovative therapeutic drugs that offer a substantial
benefit to suffering patients. In 2007, Samaritan partnered
its Phase II/III oral HIV viral-entry inhibitor drug for Phase
III development. The Company's promising memory-restoring
Alzheimer's drug, Caprospinol, expects to enter a Phase I
clinical trial after acute toxicity studies, and its High
Stress Cortisol drug intended to counteract Cushing's disease
is expected to enter Phase II clinical trials. Samaritan has
several drugs it is preparing for FDA IND status and is evaluating
the use of "SP-1000'' for hypercholesterolemia patients and
the use of "SP-30'' as an "oral treatment'' for Hepatitis-C.
In addition, Samaritan has acquired the marketing and sales
rights to sell eleven revenue-generating products in various
Eastern European countries.
Disclaimer
The company disclaims
any information created by an outside party and endorses only
information communicated by its press releases, filings, and
Website. This news release contains forward-looking statements
that reflect management's current beliefs about the potential
for its drug candidates, science, and technology. However,
as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development
and regulatory review. There are no guarantees that products
will prove to be commercially successful. For additional information
about the factors that affect the company's business, please
read the company's latest Form 10-Q filed November 19, 2007.
The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
--------------------------------------------------------------------------------
Source: Samaritan Pharmaceuticals, Inc.
|
